vincristine/uždegimas

Nuoroda įrašoma į mainų sritį

Straipsniai Klinikiniai tyrimai Patentai

Pasirinkite rūšiavimo tipą

14 rezultatus

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) of parsaclisib in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). (Phase I) II. To assess the complete metabolic response rate by positron emission tomography (PET) (PET complete response [CR]) of

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

PRIMARY OBJECTIVE: I. To determine the safest and most tolerable dose and schedule of lenalidomide to combine with etoposide, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride) (EPOCH) chemotherapy in adult T-cell

Diagnostic of Chemotherapy Induced Neuropathy in Children

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Epidemiology and suggested mechanisms involved in pediatric chemotherapy induced neuropathy: Pediatric chemotherapy induced peripheral neuropathy (CIPN) is an early (often occurring within the first three months), potentially severe long-lasting and dose limiting adverse effect of treatment in

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Hodgkin lymphoma (HL) is a lymphoid neoplasm characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells in a background of inflammatory cells. The majority of patients with HL have a good outcome with first-line chemotherapy such as ABVD (doxorubicin, bleomycin, vinblastine and

Sirolimus Plus Propranolol Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Kasabach-Merritt phenomemon (KMP) is a profound thrombocytopenia resulting from intralesional platelet trapping. It is now clear that KMP occurs with KHE and tufted angioma, not with infantile or congenital hemangiomas. KMP is typically associated with more aggressive lesions and poorer outcomes.

Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

CIPN is a common side effect of many chemotherapeutic agents and often results in dose limitation, switch to less efficacious agents or even therapy discontinuation. CIPN mainly affects sensory nerves, while motor or autonomic nerve injury is rare. Therefore, most patients with CIPN experience

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Multiple Myeloma (MM) is a B cell malignancy characterized by the presence of bone marrow infiltration by clonal plasma cells that generally secrete a monoclonal component in the serum or urine. It is the second most frequent hematological malignancy, after non-Hodgkin lymphomas, and accounts

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Background: - Kaposi sarcoma herpesvirus (KSHV)-associated primary effusion lymphoma (PEL) and large cell lymphoma arising from KSHV-MCD are aggressive B cell neoplasms with clinicopathologic and molecular profiles distinct from other AIDS-related lymphomas. - There are no prospective studies on

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

PRIMARY OBJECTIVES: I. To determine the progression-free survival (PFS) from enrollment for patients with non-bulky stage I and II Hodgkin lymphoma. II. To compare the PFS of patients who are PET positive versus PET negative following 2 cycles of doxorubicin hydrochloride, bleomycin, vinblastine,

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Background: Two signatures of the microenvironment were recently identified that are predictive of outcome in patients with newly diagnosed DLBCL treated with R-CHOP. These signatures, called stromal 1 and stromal 2 , are associated with genes expressed by infiltrating mononuclear cells. The stromal

Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The Study Drugs: Methotrexate is designed to disrupt cells from making and repairing DNA (the genetic material of cells) and "copying" themselves. Vincristine is designed to interfere with the multiplication of cancer cells, which may slow or stop their growth and spread throughout the body. This

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The Study Drugs: Vorinostat is designed to cause chemical changes in different groups of proteins that are attached to DNA (the genetic material of cells), which may slow the growth of cancer cells or cause the cancer cells to die. Cyclophosphamide is designed to interfere with the multiplication of

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Bortezomib is designed to block a protein that plays a role in cell function and growth, which may cause cancer cells to die. Rituximab is designed to attach to cancer cells, which may cause them to die. Cyclophosphamide, vincristine, doxorubicin, and cladribine are designed to interfere with the

Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Hypothesis: 5 to 7 plasma exchanges in addition to conventional therapy at onset of myeloma with acute renal failure, reduces the composite outcome of death, dialysis dependence or a GFR < 30 ml/min/1.73 meter squared at 6 months. Entry Criteria: The inclusion criteria are a new diagnosis of

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais